Quantcast

Merck, Pfizer dropping program from Phase III Javelin Ovarian PARP study

German Merck, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer are dropping the Phase III JAVELIN Ovarian PARP 100 study in which they tested avelumab combined with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV), as they described in the press release on Wednesday.

Read more

First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02, an Advanced Cancer Drug from Genzada Pharmaceuticals, at HonorHealth Research Institute

STERLING, Kan.–(BUSINESS WIRE)–Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Life Sciences Limited, announced today that the first patient

Read more

Latin America Pharmaceutical Excipients Market Outlook to 2024 by Functionality and Country – Includes Profiles on Ashland, BASF, DowDuPont, Roquette, and Kerry Group – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Latin America Pharmaceutical Excipients Market by Functionality (Fillers, Coating, Disintegrants, Binders, Lubricants, Preservatives, Emulsifying Agents, Lubricants, Glidants, Diluents),

Read more

GenomOncology names CEO

GenomOncology, a technology solution provider for oncology, named Brad Wertz as the new Chairman and Chief Executive Officer (CEO), who’ll assume the position from the start of year 2019.  Wertz has been a founding investor and chairman of the board since the beginning, and has increased his involvement as the company has grown over the past two years. 

Read more